borderline significantp=0.05
Group differences were identified in memory (p=0.02) and d’ (p=0.01), whereas the total score for ACE-III was borderline significant (p=0.05).
Group differences were identified in memory (p=0.02) and d’ (p=0.01), whereas the total score for ACE-III was borderline significant (p=0.05).
At 24-28 weeks LDL-C levels were significantly higher in the vitamin D group compared with placebo (3.99±0.96 vs 3.55±0.83, p<0.01) and showed a trend for higher levels at 35-37 wks (4.06±1.01 vs 3.68±0.93, p=0.06).
While the association with retinopathy seemed absent (OR 1.21 [95 % CI: 0.67-2.19; p = 0.538]), the association with macrovascular disease just barely failed to reach statistical significance (OR 2.47 [95 % CI: 0.92-6.65; p = 0.074]).
Lastly, we observed a statistical trend toward improved glucose tolerance in Nox4 HFD mice compared to WT HFD at 3 and 15 weeks (3 wks, p=0.09; 15 wks, p=0.09) and in insulin tolerance at 12 weeks (p=0.08).
RT decreased by a mean of 2.5 μm (SD14) in patients treated with CaD, whereas in patients treated with placebo RT increased by 3.8 μm (SD24), but this difference did not reach statistical significance (p= 0.26).
Nominally significant interactions for first event of hospitalisation for heart failure (HHF) and HHF/CV death were observed with baseline use of diuretics, including loop diuretics, with an increased benefit of ertugliflozin vs placebo (Figure).
When the pooled sample was stratified according to study-specific tertiles of REMAP a clear trend of mortality incidence rate was observed from 2.1% (96 events/505; 4522.9 person/year - py) to 2.5% (107 events/503; 4220.8 py) and 5.3% (206 events/520; 3851.1 py) in tertile 1, 2 and 3 (P for trend<0.001).
Highly significant differences in DNA methylation were observed between males and females at a number of autosomal sites.